Is NMN Legal in the Netherlands in 2026? Novel Food Status and Where to Source Legally

Nicotinamide mononucleotide — NMN — was the most-discussed longevity compound in European biohacker forums through 2022 and 2023. Then in 2024, the European Food Safety Authority and the European Commission classified NMN as a Novel Food, effectively removing it from the food supplement market across the EU. Dutch biohackers, particularly active in the longevity space and concentrated in Amsterdam and Rotterdam, were left navigating a confusing post-classification environment. Most assume NMN is now simply illegal in the Netherlands. They are wrong about three things.

This guide covers what the Novel Food classification actually means under EU law, current Dutch (NVWA) enforcement reality in 2026, three legal acquisition routes that remain available to Dutch residents, vendor due diligence for NL shipping, and what changes the upcoming EFSA review may bring. Personal experience plus published research and primary regulatory sources. No medical advice, no encouragement — clear regulatory understanding so Dutch biohackers can make informed decisions.

The EU Novel Food Classification, Explained Simply

Under the Novel Food Regulation (EU) 2015/2283, any food or food ingredient that was not consumed to a significant degree within the EU before 15 May 1997 must undergo safety authorisation before being placed on the market as a food or food supplement. NMN, despite being naturally present in trace amounts in foods like broccoli and avocado, falls into this category at supplement-relevant doses (250-1000mg/day), because such concentrations were not consumed at supplement scale before 1997.

In June 2024, the European Commission confirmed the Novel Food status of synthetic NMN, requiring formal authorisation before any product can be sold as a food supplement in the EU. As of May 2026, no authorisation has been granted. The result: NMN cannot legally be sold as a food supplement in any EU member state, including the Netherlands.

What "Cannot Be Sold as a Food Supplement" Actually Means

This is the most misunderstood part of the regulation. The Novel Food classification specifically restricts placing a substance on the market as food or food supplement (Article 6). It does not:

• Criminalise possession by individuals
• Prohibit personal import for personal use under specific conditions
• Ban sale as a non-food product (e.g., research chemical, cosmetic ingredient where applicable)
• Apply to medicinal products authorised under separate EMA pathways
• Apply outside the EU (UK, Switzerland, Norway have separate regulatory regimes)

This is the gap that defines the actual Dutch buyer's reality.

Current Dutch Legal Status: NVWA Stance in 2026

The Nederlandse Voedsel- en Warenautoriteit (NVWA) — the Netherlands Food and Consumer Product Safety Authority — enforces Novel Food Regulation domestically. The current NVWA enforcement priority is on Dutch-based vendors and online marketplaces selling NMN as a food supplement to Dutch consumers, not on individual personal-use possession.

Selling vs. Possessing

NVWA actions in 2024-2025 targeted:

• Dutch e-commerce sites listing NMN supplements with health claims
• Physical retail outlets stocking NMN-labeled food supplements
• Influencers in the Netherlands accepting paid promotion of NMN food supplements
• Wholesale and B2B distribution of NMN as a food supplement ingredient

NVWA actions did not target:

• Personal possession of NMN by Dutch residents
• Personal import for personal use in non-commercial quantities
• Sale as a research chemical to verified research entities
• Cross-border purchases from non-EU vendors for personal use

The "Research Compound" Framing

Some EU and UK vendors continue to sell NMN under "research use only" labelling, similar to how research peptides are marketed. This framing has limited legal protection in the Netherlands — if the vendor knows or should reasonably know the buyer is a private individual using it for personal supplementation, the food supplement prohibition still applies. However, NVWA enforcement has not pursued individual buyers under this scenario, focusing instead on commercial distribution.

Three Legal Acquisition Routes for Dutch Residents

Route 1: EU Compounding Pharmacies with Prescription

NMN can be prepared by EU compounding pharmacies (apotheken die magistraal bereiden) when prescribed by a licensed physician for a documented medical purpose. In practice, this requires a Dutch or other EU physician willing to prescribe NMN as a magistrale bereiding, which is uncommon but not unavailable. Functional medicine and longevity-focused private clinics in the Netherlands occasionally offer this pathway.

Realistic process: private consultation with a longevity-focused physician (€200-400), discussion of medical rationale, prescription issuance, dispensing by a compounding pharmacy. Cost per gram of pharmacy-compounded NMN is typically 3-5x retail supplement-grade pricing, but the legal posture is fully clean.

Route 2: UK and Switzerland Sourcing

The UK is no longer in the EU and is therefore not subject to the EU Novel Food Regulation directly. UK regulators have not currently classified NMN as a novel food under the equivalent UK Novel Foods Regulation (the UK regime mirrors but is separate from the EU). Several UK-based vendors continue to sell NMN supplements legally to UK customers, with the question of cross-border shipping to the EU remaining a nuanced matter.

Switzerland, as a non-EU/EFTA country, similarly is not subject to EU Novel Food rules. Swiss vendors selling NMN are operating under Bundesamt für Lebensmittelsicherheit und Veterinärwesen (BLV) rules, which currently permit NMN as a food supplement subject to safety standards.

For Dutch residents personally importing from UK or Swiss vendors: the substance crosses an EU border on entry to the Netherlands, technically engaging the Novel Food prohibition. NVWA does not currently intercept personal-use shipments of NMN at customs, but this could change with policy shifts. The legal grey zone is real but currently low-risk.

Route 3: Personal Import from Outside EU

Vendors outside the EU (US, China, Japan) ship NMN to EU addresses in routine volume. Customs declaration thresholds and personal-use exemptions apply.

Practical reality for NL shipping:

• Personal-use quantities (typically up to 3-month supply, ~90g) face minimal customs interception
• Larger commercial-volume shipments are intercepted and treated as unauthorised Novel Food import
• Declared value above €150 triggers VAT and customs declaration; unpaid VAT is the most common reason shipments are delayed at NL customs
• Documentation of prior NL shipping success is the strongest signal of vendor reliability

For a deeper compound-by-compound discussion of NMN versus NR, our NMN vs NR Europe guide covers bioavailability, dosing rationale, and the cellular pathway differences. Both compounds face similar Novel Food classification challenges in the EU.

Vendor Due Diligence for NL Shipping Addresses

If you decide to source from outside the Netherlands, vendor verification is the only meaningful risk reduction. Specific patterns we look for:

What to Verify Before Ordering

• Third-party Certificate of Analysis (COA). Independent laboratory verification of NMN identity (HPLC), purity (typically >99%), and absence of contaminants (heavy metals, microbial). Vendors who cannot provide a recent COA on request are not credible.
• Independent purity testing visible. Some premium vendors publish recent independent test results from labs like Eurofins or Labdoor on their product pages.
• Stability data. NMN degrades to nicotinamide if improperly stored or exposed to humidity. Vendors who specify storage conditions and ship with desiccant indicate quality control awareness.
• Prior NL customs success. Independent reviews from Dutch buyers showing successful delivery to NL addresses, ideally with discussion of any customs interactions.
• Form factor. Capsules with declared 250mg or 500mg per capsule are easier to handle than bulk powder. Sublingual NMN has higher bioavailability per published research but lower stability.

Red Flags

• Vendor offering NMN at a price <€0.50 per gram — identity is suspect; the substance may be nicotinamide, niacin, or NR mislabeled
• No COA available on request
• Vendor only accepts cryptocurrency payment with no fiat option
• Pharmaceutical-style packaging that increases customs-screening risk
• Bulk-discount pressure to order >200g shipments (commercial-volume interception risk)

NMN vs. NR for Dutch Buyers: A Practical Comparison

Given the regulatory landscape, the question of whether to source NMN at all (versus its precursor NR, nicotinamide riboside) is worth revisiting for Dutch buyers in 2026.

NR (nicotinamide riboside) was classified as a novel food earlier than NMN and received EU authorisation in 2017 (Niagen branded ingredient under the Chromadex monopoly), with subsequent expansion. Several NR-containing food supplements are legally sold in the Netherlands today.

For Dutch buyers prioritising legal cleanness over compound preference, NR is the easier path. For buyers committed to NMN specifically based on the published bioavailability and cellular conversion literature, the three routes above remain available. Our full NMN vs NR comparison covers the evidence base and bioavailability considerations in detail.

What Changes in 2026-2027

Two regulatory developments are worth tracking:

EFSA Safety Review

The European Food Safety Authority is conducting an ongoing safety assessment of synthetic NMN under the Novel Food authorisation process. A favourable EFSA opinion (Article 11) would clear the path for European Commission authorisation, which would re-open the legal supplement market across the EU. The earliest realistic timeline for authorisation, if granted, is mid-2027.

Member State Responses

Some EU member states (notably France, with active ANSES involvement in Novel Food matters) have signalled tighter NMN enforcement, while others (Spain, Italy) have been less proactive. The Netherlands, with its trade-friendly regulatory tradition, has so far enforced commercial distribution without aggressive personal-use enforcement.

Key Takeaways

• NMN is a Novel Food under EU Regulation 2015/2283 since June 2024. It cannot legally be sold as a food supplement in the Netherlands. No EU authorisation has been granted as of May 2026.
• The Novel Food prohibition restricts placing on the market as food. It does not criminalise personal possession or personal-use import in non-commercial quantities.
• NVWA enforcement targets Dutch-based commercial distribution, not individual personal-use buyers.
• Three legal acquisition routes remain available: EU compounding pharmacy with prescription, UK/Swiss sourcing (non-EU regulatory regimes), and personal import from outside EU.
• Vendor due diligence is the primary risk reduction: verified third-party COA, independent purity testing, prior NL shipping success, stable form factor.
• NR (nicotinamide riboside) is EU-authorised and sold legally as a supplement in NL. For buyers prioritising legal cleanness, NR is the easier path.
• EFSA is reviewing NMN safety. Favourable opinion + EC authorisation could re-open the EU supplement market, earliest realistic timeline mid-2027.